Acquired by AbbVie in Feb 2024
IMGN - ImmunoGen, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Waltham,
United States
Type: Equity
IMGN price evolution
IMGN
| (in millions $) | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 | 31 Jan 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $605.53 | $571.99 | $201.25 | $275.14 |
| Short term investments | ||||
| Net receivables | $137.16 | $79.96 | $31.05 | $17.98 |
| Inventory | $33.77 | $21.21 | $16.91 | $16.2 |
| Total current assets | $766.9 | $669.27 | $243.86 | $304.12 |
| Long term investments | ||||
| Property, plant & equipment | $12.77 | $12.77 | $13.69 | $14.61 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $55.2 | $45.05 | $44.48 | $44.81 |
| Total investments | ||||
| Total assets | $822.1 | $714.33 | $288.35 | $348.94 |
| Current liabilities | ||||
| Accounts payable | $24.85 | $18.44 | $32.26 | $45.35 |
| Deferred revenue | $63.9 | $44.61 | $47.5 | $50.21 |
| Short long term debt | $4.46 | $4.33 | $4.21 | $4.1 |
| Total current liabilities | $134.66 | $93.7 | $101.63 | $121.86 |
| Long term debt | $79.87 | $80.88 | $10.05 | $11.15 |
| Total noncurrent liabilities | $125.84 | $129.78 | $64.8 | $71.25 |
| Total debt | $84.33 | $85.21 | $14.26 | $15.24 |
| Total liabilities | $260.5 | $223.49 | $166.43 | $193.11 |
| Shareholders' equity | ||||
| Retained earnings | -$1708.59 | -$1739.33 | -$1735.09 | -$1694.07 |
| Other shareholder equity | ||||
| Total shareholder equity | $561.6 | $490.84 | $121.92 | $155.83 |
| (in millions $) | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $275.14 | $478.75 | $293.86 | $176.22 |
| Short term investments | ||||
| Net receivables | $17.98 | $10.93 | $22.5 | $23.62 |
| Inventory | $16.2 | |||
| Total current assets | $304.12 | $500 | $324.25 | $208.9 |
| Long term investments | ||||
| Property, plant & equipment | $14.61 | $17.05 | $19.83 | $22.58 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $44.81 | $25.77 | $30.82 | $26.36 |
| Total investments | ||||
| Total assets | $348.94 | $525.76 | $355.07 | $235.26 |
| Current liabilities | ||||
| Accounts payable | $45.35 | $18.43 | $9.54 | $9.93 |
| Deferred revenue | $50.21 | $92.07 | $110.11 | $127.43 |
| Short long term debt | $4.1 | $3.54 | $5.24 | $2.97 |
| Total current liabilities | $121.86 | $100.94 | $122.32 | $77.41 |
| Long term debt | $11.15 | $15.24 | $18.65 | $23.88 |
| Total noncurrent liabilities | $71.25 | $99.23 | $143.18 | $233.97 |
| Total debt | $15.24 | $18.78 | $23.89 | $26.85 |
| Total liabilities | $193.11 | $200.18 | $265.5 | $311.38 |
| Shareholders' equity | ||||
| Retained earnings | -$1694.07 | -$1471.14 | -$1331.84 | -$1287.47 |
| Other shareholder equity | $325.59 | |||
| Total shareholder equity | $155.83 | $325.59 | $89.57 | -$76.12 |
| (in millions $) | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 | 31 Dec 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $113.42 | $83.15 | $49.87 | $41.17 |
| Cost of revenue | $2.15 | $0.91 | $0.63 | $0.18 |
| Gross Profit | $111.27 | $82.24 | $49.24 | $40.99 |
| Operating activities | ||||
| Research & development | $47.57 | $50.08 | $51.62 | $58.48 |
| Selling, general & administrative | $37.74 | $36.36 | $40.02 | $42.06 |
| Total operating expenses | $85.31 | $86.43 | $91.64 | $100.55 |
| Operating income | $25.96 | -$4.19 | -$42.39 | -$59.56 |
| Income from continuing operations | ||||
| EBIT | $32.12 | -$0.05 | -$41.01 | -$57.79 |
| Income tax expense | -$1.17 | $0.88 | $1.22 | |
| Interest expense | $2.54 | $3.32 | ||
| Net income | ||||
| Net income | $30.75 | -$4.25 | -$41.01 | -$59.01 |
| Income (for common shares) | $30.75 | -$4.25 | -$41.01 | -$59.01 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $108.78 | $69.86 | $132.3 | $82.27 |
| Cost of revenue | $0.18 | |||
| Gross Profit | $108.61 | $69.86 | $132.3 | $82.27 |
| Operating activities | ||||
| Research & development | $213.37 | $151.12 | $114.59 | $114.52 |
| Selling, general & administrative | $116.13 | $43.81 | $38.6 | $38.49 |
| Total operating expenses | $329.5 | $194.93 | $154.68 | $174.44 |
| Operating income | -$220.89 | -$125.07 | -$22.38 | -$92.17 |
| Income from continuing operations | ||||
| EBIT | -$221.71 | -$139.26 | -$44.28 | -$104.04 |
| Income tax expense | $1.22 | |||
| Interest expense | $0.05 | $0.1 | $0.1 | |
| Net income | ||||
| Net income | -$222.93 | -$139.3 | -$44.37 | -$104.13 |
| Income (for common shares) | -$222.93 | -$139.3 | -$44.37 | -$104.13 |
| (in millions $) | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 | 31 Dec 2022 |
|---|---|---|---|---|
| Net income | $30.75 | -$4.25 | -$41.01 | -$59.01 |
| Operating activities | ||||
| Depreciation | $0.42 | $0.43 | $0.45 | $0.43 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $7.87 | $7.43 | $7.07 | $10.75 |
| Total cash flows from operations | $2.77 | -$66.74 | -$73.72 | -$60.2 |
| Investing activities | ||||
| Capital expenditures | -$1.35 | -$0.08 | -$0.21 | -$0.25 |
| Investments | ||||
| Total cash flows from investing | -$1.35 | -$0.08 | -$0.21 | -$0.25 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $32.13 | $365.74 | $0.04 | $26.07 |
| Net borrowings | $71.82 | |||
| Total cash flows from financing | $32.13 | $437.56 | $0.04 | $26.07 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $33.55 | $370.74 | -$73.89 | -$34.37 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Net income | -$222.93 | -$139.3 | -$44.37 | -$104.13 |
| Operating activities | ||||
| Depreciation | $1.78 | $2.02 | $2.1 | $4.03 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $25.61 | $17.48 | $14.32 | $14.17 |
| Total cash flows from operations | -$229.8 | -$169.42 | -$78.62 | -$88.37 |
| Investing activities | ||||
| Capital expenditures | -$1.36 | -$1.43 | $0.51 | -$0.53 |
| Investments | ||||
| Total cash flows from investing | -$1.36 | -$1.43 | $0.51 | -$0.53 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $27.55 | $356.84 | $195.74 | $2.87 |
| Net borrowings | -$1.1 | |||
| Total cash flows from financing | $27.55 | $355.74 | $195.74 | $2.87 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$203.61 | $184.89 | $117.63 | -$86.03 |
News
|
AbbVie: An Undervalued Giant
GuruFocus.com via Yahoo Finance
27 Mar 2024
|
|
Is First Trust Mid Cap Core AlphaDEX ETF (FNX) a Strong ETF Right Now?
Zacks via Yahoo Finance
27 Mar 2024
|
|
AbbVie (ABBV) to Buy Landos to Strengthen Autoimmune Portfolio
Zacks via Yahoo Finance
26 Mar 2024
|
|
Why Is Ulcerative Colitis-Focused Landos Biopharma Stock Trading Higher On Monday? - Landos...
Benzinga
25 Mar 2024
|
|
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
Zacks via Yahoo Finance
25 Mar 2024
|
|
FDA grants full approval to AbbVie/ImmunoGen drug Elahere (NYSE:ABBV)
Seeking Alpha
22 Mar 2024
|
|
Stocks Rally as AI Craze Sweeps Across the World: Markets Wrap
Bloomberg via Yahoo Finance
22 Feb 2024
|
|
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
Zacks via Yahoo Finance
22 Feb 2024
|
|
11 Best Small-Cap Growth Stocks to Invest In
Insider Monkey via Yahoo Finance
22 Feb 2024
|
|
AbbVie (ABBV) Announces Appointment of New CEO Robert Michael
Zacks via Yahoo Finance
21 Feb 2024
|
Fundamentals
| Market cap | $8.30B |
|---|---|
| Enterprise value | $7.78B |
| Shares outstanding | 265.84M |
| Revenue | $287.61M |
|---|---|
| EBITDA | -$65.01M |
| EBIT | -$66.74M |
| Net Income | -$73.52M |
| Revenue Q/Q | 637.72% |
| Revenue Y/Y | N/A |
| P/E ratio | -112.92 |
|---|---|
| EV/Sales | 27.05 |
| EV/EBITDA | -119.69 |
| EV/EBIT | -116.59 |
| P/S ratio | 28.87 |
| P/B ratio | 14.78 |
| Book/Share | 2.11 |
| Cash/Share | 2.28 |
| EPS | -$0.28 |
|---|---|
| ROA | -13.53% |
| ROE | -22.11% |
| Debt/Equity | 1.24 |
|---|---|
| Net debt/EBITDA | 5.31 |
| Current ratio | 5.70 |
| Quick ratio | 5.44 |